Hikma Pharmaceuticals PLC 2016 AR2
The report highlights Hikma Pharmaceuticals PLC's strategic and financial performance for 2016, a year characterized by the transformational acquisition of West-Ward Columbus. The company achieved a 35% revenue growth to reach approximately $2.0 billion, driven by strong performance in its Injectables business. In sustainability, Hikma continued its commitment to the UN Global Compact and was recognized as a constituent of the FTSE4Good index. The company also disclosed its greenhouse gas emissions, showing a 2.9% absolute decrease in emissions compared to 2015.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2016
Type: AR2
Pages: 218
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's strategic and financial performance for 2016, a year characterized by the transformational acquisition of West-Ward Columbus. The company achieved a 35% revenue growth to reach approximately $2.0 billion, driven by strong performance in its Injectables business. In sustainability, Hikma continued its commitment to the UN Global Compact and was recognized as a constituent of the FTSE4Good index. The company also disclosed its greenhouse gas emissions, showing a 2.9% absolute decrease in emissions compared to 2015.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees